Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Nov 19, 2024 12:16pm
63 Views
Post# 36319952

RE:RE:RE:RE:How does Accelerated Approval work

RE:RE:RE:RE:How does Accelerated Approval work As previously posted :  Accelerated Approval provides for a drug to receive a conditional FDA marketing approval based on surrogate endpoints that have demonstrated a clinical benefit, An Accelerated Approval is granted well before a Registrational BLA is filed, and an AA requires the sponsor to run a confirmatory clinical trial on which the FDA decides to grant full marketing approval. The FDA's full marketing approval follows the sponsor registering (filing) a Biological Licensing Application (BLA) on the final results of the confirmatory / registration enabling clinical trial.

Registration Enabling Clinical Trial means (a) a hyman clinical trial of a product that would satisfy the requirements of U.S. 21 C.F.R. Part 312.21(c), as amemded, and is intended to (i) establish that the productis safe and efficacious for its intended use, (ii) define contraindications, warnings, precautions and adverse reactions that are associate with the product in the dosage range to be prescribed, and (iii) support Regulatory Approval for such product, or (b) a similar clinical study prescribed by the relevant Regulatory authorities in a country other than the United States.
<< Previous
Bullboard Posts
Next >>